Full read review of Hydryoxychloroquine -its pharmacology, MOA (eg, blocking TLR 7 & 9), Dz specific efficacy and adverse effects https://t.co/WVErW1RrCj https://t.co/eQVFIZNSRx

Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene Presentation by Dr. Alana Haussmann at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/LRsT1TLEm4 https://t.co/bSi50pDn2O

Opioid Deaths are Down (2.28.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week! https://t.co/Lb6F64AlNJ https://t.co/7AjSXOn142

Loss of Good Sleep Linked to All-Cause Mortality A US study shows that nearly two-thirds of the population had suboptimal 5-year sleep duration trajectories with a resultant 29% increase in risk of all-cause mortality. https://t.co/GXkIDC2uSQ https://t.co/wYzpnK9BMQ

Recurrent Pericarditis in Lupus A study from the Lupus Hopkins Cohort shows that systemic lupus erythematosus (SLE) patients with pericarditis are at risk for recurrence, and likely to be younger patients, with uncontrolled disease, and linkage to higher doses of oral… https://t.co/hML8NfhBy3 https://t.co/cKX5KaSg3a

Risk of Cancer on JAKi in RA (12 463 vs 38 345 controls). No incr risk of CA w/ exposure to JAKi (adj OR 1.04), TNFi (0.98), other bDMARDs (0.98). But JAKi was assoc w/ signif more lung CA (1.40; esp in males 2.12) & less breast CA (0.62) in women https://t.co/fr3VjPhJve https://t.co/zNehdWBbeI

Selective mutation of Traf1/cIAP2 (V196) interaction attenuates inflammatory responses that may contribute to rheumatoid arthritis activity. THis may lead to a new class of therapies for RA https://t.co/kYqAqGsSEA https://t.co/JWUN6iTvxa

I ALWAYS recommend paraffin wax baths for stiffness, RA, OA, PSS, etc. Here are some instructions for home use https://t.co/CTI4K2kHf9 https://t.co/i0kO99vdYc

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis https://t.co/WP8JGpHc6p https://t.co/x9m870mCJ4

UK MRCP exam makeup: Cardio 15% Pharm 15% Resp 10% GI 10% Neuro 10% ID 8% Endo 8% RHEUM 6% Heme 5% Renal 5% Derm 4% Eye 2% Psych 2% https://t.co/WG7X3B8a0Y https://t.co/9VF5LkLJjs

Cochrane review of TNF inhib. in #JIA shows TNFi efficacy, but uncertainty about LT safety, pain, function, & Dz control - esp compared to MTX. 9 studies, 678 JIApts, age 8-15 yrs (80% F), Dz duration 0.8-6.7 yrs. Withdrawls 1% v 3%; Serious AE 6% v 7% (PBO vs TNFi).… https://t.co/i35m5uzG1m https://t.co/VzJN9PmmMh

"Never take the advice of someone who has not had your kind of trouble" - Sidney J. Harris https://t.co/xdB6u6OiPq